Biomarkers of ovarian response: current and future applications

Slides:

Advertisements

Similar presentations

Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles Ryan G. Steward,

Advertisements

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis

Clinically significant and sustained weight loss is achievable in obese women with polycystic ovary syndrome followed in a regular medical practice Lysanne.

Yuqian Cui, M. D. , Ph. D. , Yuhua Shi, M. D. , Ph. D. , Linlin Cui, M

Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study Thi.

Developmental capacity of in vitro–matured human oocytes retrieved from polycystic ovary syndrome ovaries containing no follicles larger than 6 mm Luis.

Antral follicle count (AFC) can be used in the prediction of ovarian response but cannot predict the oocyte/embryo quality or the in vitro fertilization.

Karl R. Hansen, M. D. , Ph. D. , George M. Hodnett, M. D

Does the time interval between antimüllerian hormone serum sampling and initiation of ovarian stimulation affect its predictive ability in in vitro fertilization–intracytoplasmic.

Risk of obstructive sleep apnea in obese and nonobese women with polycystic ovary syndrome and healthy reproductively normal women Babak Mokhlesi, M.D.,

H. Irene Su, M. D. , M. S. C. E. , Mary D. Sammel, Sc. D. , Michael V

Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor.

The association between circulating levels of antimüllerian hormone and follicle number, androgens, and menstrual cycle characteristics in young women

Mike Ripley, M. D. , F. R. C. S. C. , Andrea Lanes, M. Sc

Janet Kwee, M. D. , Roel Schats, M. D. , Ph. D. , Joseph McDonnell, M

Sperm DNA damage measured by the alkaline Comet assay as an independent predictor of male infertility and in vitro fertilization success Luke Simon,

Patient-tailored ovarian stimulation for in vitro fertilization

Zhi-Yong Yang, M.D., Ri-Cheng Chian, Ph.D. Fertility and Sterility

Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) in IVF patients with polycystic ovary syndrome: correlations with outcome

Neohormones as biomarkers of reproductive health

Ethnicity as a determinant of ovarian reserve: differences in ovarian aging between Spanish and Indian women Carlos Iglesias, M.D., Manish Banker, M.D.,

Antimüllerian hormone levels and antral follicle count as prognostic indicators in a personalized prediction model of live birth Scott M. Nelson, M.R.C.O.G.,

Risk of depression and other mental health disorders in women with polycystic ovary syndrome: a longitudinal study Angela Kerchner, B.A., Whitney Lester,

Robert A. Wild, M. D. , Manfredi Rizzo, M. D. , Sheri Clifton, Ph. D

Antimüllerian hormone as a predictor of live birth following assisted reproduction: an analysis of 85,062 fresh and thawed cycles from the Society for.

Antimüllerian hormone levels and antral follicle counts are not reduced compared with community controls in patients with rigorously defined unexplained.

Ovarian stimulation protocols for IVF: is more better than less?

The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count Simone L. Broer, B.Sc., Ben Willem J.

Genotypically determined ancestry across an infertile population: ovarian reserve and response parameters are not influenced by continental origin Meir.

Rebecca A. Feldman, M. D. , Kathleen O'Neill, M. D. , Samantha F

FSH receptor, KL1/2, P450, and PAPP genes in granulosa-lutein cells from in vitro fertilization patients show a different expression pattern depending.

The role of steroid hormone supplementation in non–assisted reproductive technology treatments for unexplained infertility Alexander M. Quaas, M.D.,

A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data

Evaluating the performance of serum antimullerian hormone concentration in predicting the live birth rate of controlled ovarian stimulation and intrauterine.

Deleterious effect of tobacco on IVF outcome and ovarian reserve as reflected by serum anti mullerian hormone (AMH) P. Barriere, T. Freour, D. Masson,

Epidemiology and Adverse Cardiovascular Disease (CVD) Risk Profile of Polycystic Ovarian Syndrome (PCOS): The Kaiser Permanente Polycystic Ovarian Syndrome.

Modification of the Beckman-Coulter second-generation enzyme-linked immunosorbent assay protocol improves the reliability of serum antimüllerian hormone.

Evaluation of serum antimullerian hormone and inhibin B concentrations in the differential diagnosis of secondary oligoamenorrhea Hang Wun Raymond Li,

Effects of acupuncture on pregnancy rates in women undergoing in vitro fertilization: a systematic review and meta-analysis Cui Hong Zheng, M.D., Ph.D.,

Albert Hsu, M. D. , Margaret Arny, Ph. D. , Alexander B. Knee, M. S

Raising threshold for diagnosis of polycystic ovary syndrome excludes population of patients with metabolic risk Molly M. Quinn, M.D., Chia-Ning Kao,

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis

Impact of pituitary suppression on antral follicle count and oocyte recovery after ovarian stimulation Nam D. Tran, M.D., Ph.D., Lusine Aghajanova, M.D.,

Tomer Singer, M. D. , David H. Barad, M. D. , M. S

Antimüllerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis Reshef Tal,

Comparison of antimüllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis.

Treatment of Ovarian Hyperstimulation Syndrome Utilizing a Dopamine Agonist and Gonadotropin Releasing Hormone antagonist N. Rollene, M. Amols, S. Hudson,

Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D.

Increased secretion of amylin in women with polycystic ovary syndrome

Prospective cohort study of three- versus two-dimensional ultrasound for prediction of oocyte maturity Doron Shmorgun, M.D., Edward Hughes, M.D., Patrick.

Fleur R. Cattrall, M. B. B. S. , Beverley J. Vollenhoven, M. B. B. S

Ri-Cheng Chian, Ph.D., Peter S. Uzelac, M.D., Geeta Nargund, M.D.

S. Samuel Kim, M.D. Fertility and Sterility

Impact of laparoscopic ovarian drilling on anti-Müllerian hormone levels and ovarian stromal blood flow using three-dimensional power Doppler in women.

Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin Samuel S. Thatcher, M.D., Ph.D., Elizabeth M.

Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis.

L. Scott, J. Bernsten, K. DeLegge, J. Hill, N. Ramsing

Progesterone-to-follicle index is better correlated with in vitro fertilization cycle outcome than blood progesterone level Yoel Shufaro, M.D., Ph.D.,

Antral follicle counts are strongly associated with live-birth rates after assisted reproduction, with superior treatment outcome in women with polycystic.

Paolo Moghetti, M.D. Fertility and Sterility

A woman with premature ovarian failure induced by Tripterygium wilfordii Hook.f. gives birth to a healthy child Xin Chen, M.D., M.Sc., Shi-ling Chen,

Tsan-Hon Liou, M. D. , Ph. D. , Jen-Hung Yang, M. D. , Ph. D

Comparing anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) as predictors of ovarian function David H. Barad, M.D., M.S., Andrea Weghofer,

Cem Fiçicioǧlu, M. D. , Tayfun Kutlu, M. D. , Elif Baglam, M. D

Evidence of absence or absence of evidence

A novel “delayed start” protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders Hakan Cakmak, M.D., Nam D. Tran,

Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing.

A prospective, comparative analysis of anti-Müllerian hormone, inhibin-B, and three- dimensional ultrasound determinants of ovarian reserve in the prediction.

Comparisons of inhibin B versus antimüllerian hormone in poor ovarian responders undergoing in vitro fertilization Rongrong Tan, M.M.Sc., Danhua Pu,

Low body mass index compromises live birth rate in fresh transfer in vitro fertilization cycles: a retrospective study in a Chinese population Jiali.

Presentation transcript:

Biomarkers of ovarian response: current and future applications Scott M. Nelson, Ph.D. Fertility and Sterility Volume 99, Issue 4, Pages 963-969 (March 2013) DOI: 10.1016/j.fertnstert.2012.11.051 Copyright © 2013 American Society for Reproductive Medicine Terms and Conditions

Figure 1 Scatter plots and correlations (Pearson correlation coefficients) for log 10 primordial follicle (PF) counts versus ovarian reserve test results. Adapted with permission from Hansen et al., 2011 (2). Fertility and Sterility 2013 99, 963-969DOI: (10.1016/j.fertnstert.2012.11.051) Copyright © 2013 American Society for Reproductive Medicine Terms and Conditions

Figure 2 Antimüllerian hormone (AMH) stratified individualization of treatment as used by the author. Ovarian response categories dictate risk, and treatment strategies are designed to minimize risk while maximizing oocyte yield within each response category. Negligible response means that the conventional criteria for triggering (three follicles ≥17 mm) is unlikely to be achieved. For all antagonist cycles with an excessive response, an agonist trigger is adopted. The AMH measurements are for the AMH Gen II assay, and the values are in pmol/L. The suggested antral follicle count (AFC) thresholds are based on the correlation of AMH and AFC and associated response category literature (30, 65). Fertility and Sterility 2013 99, 963-969DOI: (10.1016/j.fertnstert.2012.11.051) Copyright © 2013 American Society for Reproductive Medicine Terms and Conditions

Figure 3 Potential clinical applications of antimüllerian hormone (AMH) by health-care providers. IVF = in vitro fertilization; PCOS = polycystic ovary syndrome; hypog hypog = hypogonadotrophic hypogonadism; POI = premature ovarian insufficiency. Fertility and Sterility 2013 99, 963-969DOI: (10.1016/j.fertnstert.2012.11.051) Copyright © 2013 American Society for Reproductive Medicine Terms and Conditions